Six names on the slate today, and one of them is a smoking crater.

Six names on the slate today, and one of them is a smoking crater.

Start with the crater. Alnylam Pharmaceuticals gapped down twenty-eight point three percent on the print — the single worst reaction on the board. Revenue grew eighty-two point six percent year over year, which sounds extraordinary until you understand that RNA interference drugs carry brutal clinical and commercial binary risk, and what the Street was pricing was a cleaner path to that next approval cycle. Net margin at thirteen point five on a fifty-times earnings multiple means you were paying for a pipeline story, and the pipeline just got complicated. When a biotech with that revenue growth still drops nearly thirty percent, the market is not reacting to the quarter — it is repricing the entire forward probability. Watch what management says about trial timelines on the call, because that is the only number that matters now.

Amazon gapped up three point nine percent, and the number that explains it is the net margin: twelve point two percent on a company this size, growing revenue fourteen point two percent year over year while earnings per share expanded thirty-six point five percent. The Street keeps underwriting Amazon as a retail business. The filing will show you it is a margin compounding machine with a retail wrapper. Twenty-seven point eight times earnings for that profile is not expensive — it is the question every fundamental shop has to answer.

Apple was down one point four percent despite twenty-nine percent earnings per share growth on twelve point eight percent revenue growth, and that gap tells you the story: the multiple at nearly forty times is pricing perfection, and any geographic revenue softness or services deceleration in the segment detail will be treated as a crack in the foundation.

Arthur J. Gallagher dropped four point six percent and the line that matters is earnings per share down four point seven percent year over year while revenue grew twenty-four point five percent. Acquisitive insurance brokers are supposed to convert top-line into earnings — when they stop doing that, the market wants to know where the margin went and how much of it was integration cost versus something structural. Forty-one times earnings is a high price for a quarter where the bottom line moved backward.

The two utilities, American Electric Power and Ameren, barely moved — down one point three and one point one percent respectively. Both delivered earnings per share growth above twenty percent with mid-teens revenue growth, and both trade around nineteen to twenty times earnings. For regulated utilities, that is a stretched multiple even with the AI infrastructure power demand tailwind underneath them. Solid execution, but the valuation is doing real work here.

Coming days, I am going deep on two names. Alnylam gets the full teardown — that gap deserves a proper autopsy. And Amazon, because the margin architecture in that filing is more interesting than the headline, and most people will read the wrong number.

That is the menu. The filings are already public — most people just do not read them. See you at the next one.